Cambrex completes High Point expansion
Submitted by:
Andrew Warmington
Cambrex has completed a $38 million expansion at its small molecule API facility in High Point, North Carolina. This doubles capacity, with new analytical and chemical development laboratories, two new clinical manufacturing suites and a small-scale commercial manufacturing operation with three work centres and 2,000 litre reactors. Work originally began in 2021. This has created about 70 jobs.
The company added that these capabilities complement those of Snapdragon Chemistry, which it acquired earlier this year and which specialises in R&D for API batch and continuous flow process development. The combination, Cambrex said, “allows clients to utilise one vendor for flow chemistry scale-up from R&D through commercialisation”.